Core Laboratories Inc.
CLB
$12.65
$0.131.04%
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 2.31% | -11.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.31% | -11.90% | |||
| Cost of Revenue | -0.69% | -6.80% | |||
| Gross Profit | 17.82% | -31.37% | |||
| SG&A Expenses | -26.17% | 39.24% | |||
| Depreciation & Amortization | 1.62% | 2.62% | |||
| Other Operating Expenses | 3.16% | -6.15% | |||
| Total Operating Expenses | -3.66% | -2.70% | |||
| Operating Income | 365.16% | -86.95% | |||
| Income Before Tax | 727.99% | -107.59% | |||
| Income Tax Expenses | 301.99% | -103.10% | |||
| Earnings from Continuing Operations | 869.99% | -114.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 538.89% | 80.11% | |||
| Net Income | 854.88% | -115.95% | |||
| EBIT | 365.16% | -86.95% | |||
| EBITDA | 126.60% | -69.45% | |||
| EPS Basic | 856.73% | -116.13% | |||
| Normalized Basic EPS | 530.26% | -112.09% | |||
| EPS Diluted | 747.00% | -118.87% | |||
| Normalized Diluted EPS | 522.05% | -112.09% | |||
| Average Basic Shares Outstanding | -0.09% | -1.34% | |||
| Average Diluted Shares Outstanding | 1.75% | -1.34% | |||
| Dividend Per Share | 0.00% | 0.00% | |||
| Payout Ratio | 1.13% | -7.19% | |||